TSH Board of Directors resolved to convene the
2022 Annual General Shareholders' Meeting
Date of events
2022/03/04
To which item it meets
paragraph 17
Statement
1.Date of the board of directors resolution:2022/03/04
2.General shareholders' meeting date:2022/05/25
3.General shareholders' meeting location:
International Convention Center of Nangang Software Park
(Building A, 2nd Floor, No.19-10, Sanchong Rd., Nangang Dist.,
Taipei City, Taiwan)
4.Cause for convening the meeting I.Reported matters:
(1)Year 2021 Business Report
(2)Audit Committee's Review Report on the year 2021 Financial Statements
(3)Report on Employees' and Directors' Remuneration for the year 2021
5.Cause for convening the meeting II.Acknowledged matters:
(1)Year 2021 Business Report and Financial Statements
(2)Year 2021 Earnings Distribution
6.Cause for convening the meeting III.Matters for Discussion:
(1)Amendments to the "Procedures for Election of Directors"
(2)Amendments to the "Procedures for the Acquisition and Disposal of Assets"
7.Cause for convening the meeting IV.Election matters:
By-election for an independent director
8.Cause for convening the meeting V.Other Proposals:None
9.Cause for convening the meeting VI.Extemporary Motions:None
10.Book closure starting date:2022/03/27
11.Book closure ending date:2022/05/25
12.Whether to announce proposal for profit distribution
or loss off-setting in "Status of dividend distribution
" section of MOPS:Yes
13.Please explain the reason for not announcing proposal
for profit distribution or loss off-setting:N/A
14.Any other matters that need to be specified:
According to Article 172-1 and 192-1 of the Company Act,a shareholder
holding 1% or more of the total number of issued shares may submit a
written proposal for discussion and nomination of independent director
at a regular shareholders' meeting from 2022/3/21 to 2022/3/31 17:00.
Location for shareholders' submission of proposal: Administration Department,
Building G, 3F-1, No.3-1, Park St., Nangang Dist., Taipei City, Taiwan.
Tel: (02)2655-8525
Attachments
Original Link
Original Document
Permalink
Disclaimer
TSH Biopharm Corporation Ltd. published this content on 04 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 March 2022 09:25:05 UTC.
Tsh biopham corporation ltd. is a Taiwan-based company principally engaged in the manufacturing and distribution of medical preparations. The Company primarily provides medicines for cardiovascular, including Amtrel, Rytmonorm, Licodin, Isormol and ISOPTIN SR; medicines for intestines and stomach, including MOPRIDE, Catilon, Gastro-Timelet and Ribarin, and medicines for central nervous, including Aleviatin, Lonine and Lacoxa SR. The Company distributes its products mainly in domestic markets.
TSH BIOPHARM CORPORATION LIMITED 
